Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Archives
Print | Email | Share | Comments (0)

ARB Drug Controls Blood Pressure and Protects Kidneys


Jan 1, 2003

Irbesartan (Avapro), an angiotensin II receptor blocker (ARB), reduces 24-hour systolic and diastolic blood pressure as well as albumin excretion rate (AER) in people with type 2 diabetes.

Researchers at the University of Naples in Naples, Italy, observed 64 men with type 2 who had an average age of 60 years as well as similar body mass indexes, A1C levels and diabetes duration. The men were divided into two groups: those with microalbuminuria (abnormal levels of the protein albumin in the urine) and high blood pressure, and those with microalbuminuria and normal blood pressure.

Participants received either 150 mg doses of Avapro twice daily or a placebo for 60 days. After 15 days of washout, the placebo group also received Avapro.

In participants with microalbuminuria and high blood pressure, Avapro reduced 24-hour systolic and diastolic pressure and AER. In participants with microalbuminuria and normal blood pressure, Avapro reduced AER.

The researchers conclude that Avapro's beneficial effects on AER are independent of its anti-hypertensive effects.

Previous research has also demonstrated that the ACE inhibitor drug class can provide the same benefit.

* * *

Diabetes Care, November 2002


Categories: A1c Test, Diabetes, Diabetes, Heart Care & Heart Disease, International, Kidney Care (Nephropathy), Research, Type 2 Issues, Type 2 Medications



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.